HC Wainwright & Co. Upgrades Cardiff Oncology to Buy, Announces $9 Price Target

Benzinga · 2d ago
HC Wainwright & Co. analyst Robert Burns upgrades Cardiff Oncology (NASDAQ:CRDF) from Neutral to Buy and announces $9 price target.